ANR: Anatara Update on GaRP Irritable Bowel Syndrome Trial

ANATARA LIFESCIENCES LTD

• Preliminary data from the first 31 ITT participants in Anatara Lifesciences' GaRP - IBS trial encourages continuation and preparation for Stage 2.
• No safety concerns have been reported across participant groups, and the DSMB supports continuation of the trial protocol.
• Formal interim analysis is expected in late Q3 CY2023 after completion of Stage 1 by all participants.

2023-06-06 08:19:00

ANR: Anatara Company Update

ANATARA LIFESCIENCES LTD

• Anatara Lifesciences provided an update on the "GaRP" trial for Irritable Bowel Syndrome (IBS).
• The trial is on track with enrollment and randomisation onto product and placebo having resumed.
• The interim read-out of results is anticipated in early Q3 CY2023.

2023-03-10 09:05:00

ANR: Appendix 4C & Q2 FY23 Activities Report

ANATARA LIFESCIENCES LTD

1. Revised protocol for Irritable Bowel Syndrome (IBS) trial of “GaRP” 200 patient trial successfully implemented and enrolment on track for interim read-out of results anticipated to be no later than in Q2CY2023.
2. Capital raise by $865,000 Placement and completion of Entitlement Offer to existing shareholders with $524, 691 received.
3. Board changes with appointment Mr. Nicholas Haslam as non-executive director.

2023-01-12 08:21:00